Q2 EPS Forecast for ORIC Pharmaceuticals Raised by Analyst

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Equities researchers at Wedbush upped their Q2 2025 earnings per share (EPS) estimates for shares of ORIC Pharmaceuticals in a research note issued to investors on Monday, May 5th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.48) per share for the quarter, up from their previous forecast of ($0.49). Wedbush currently has a “Outperform” rating and a $20.00 target price on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.17) per share. Wedbush also issued estimates for ORIC Pharmaceuticals’ Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.84) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.90) EPS and FY2028 earnings at ($1.24) EPS.

Other analysts have also issued reports about the stock. Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co. boosted their price objective on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday. Finally, Oppenheimer dropped their price target on shares of ORIC Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $19.17.

ORIC Pharmaceuticals Stock Down 6.7 %

NASDAQ:ORIC opened at $4.70 on Thursday. ORIC Pharmaceuticals has a 52 week low of $3.90 and a 52 week high of $14.67. The stock’s fifty day moving average is $5.99 and its two-hundred day moving average is $8.12. The company has a market capitalization of $334.10 million, a P/E ratio of -2.58 and a beta of 1.37.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09.

Institutional Trading of ORIC Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in ORIC Pharmaceuticals during the fourth quarter worth approximately $50,000. Arizona State Retirement System acquired a new stake in shares of ORIC Pharmaceuticals during the first quarter worth about $56,000. BNP Paribas Financial Markets acquired a new position in ORIC Pharmaceuticals in the 4th quarter valued at about $71,000. PNC Financial Services Group Inc. raised its stake in ORIC Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock valued at $109,000 after acquiring an additional 2,520 shares during the last quarter. Finally, Legato Capital Management LLC acquired a new stake in ORIC Pharmaceuticals during the 1st quarter worth approximately $109,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.